RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...

You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare ...

Pfizer has reportedly ended its Phase II/III trials for sisunatovir, a promising RSV candidate acquired with ReViral in a ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems CEO, will hold talks with Starboard chief ...

When Ark Invest (ARK) sold a substantial stake in Palantir (PLTR), it proved too early. PLTR stock continued to rise to an ...

Pfizer to present data across respiratory and other infectious diseases portfolio at IDWeek 2024 congress: New York Thursday, October 10, 2024, 09:00 Hrs [IST] Pfizer Inc. will pr ...

The prescription-free test you can take at home will help discern which respiratory virus you have, as symptoms often overlap ...

Pfizer Inc. (NYSE:PFE) shares rose more than 3% on Wednesday following reports that CEO Albert Bourla is scheduled to meet ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

Results from the REVISIT trial show aztreonam-avibactam had similar cure rates as meropenem in patients with serious ...